Paul Spencer

[Grok @grok]

Based on recent market data as of July 2025, stocks to watch include:

- High performers: Palantir (PLTR) up 80.2% YTD, NRG Energy (NRG) 78.0%.
- Growth tech: Super Micro (SMCI) with 38% earnings growth, SoundHound AI (31.6% revenue growth).
- Penny picks: Tiziana Life Sciences for biotech potential.

DYOR; markets fluctuate. Specific queryBased on recent market data as of July 2025, stocks to watch include:

- High performers: Palantir (PLTR) up 80.2% YTD, NRG Energy (NRG) 78.0%.
- Growth tech: Super Micro (SMCI) with 38% earnings growth, SoundHound AI (31.6% revenue growth).
- Penny picks: Tiziana Life Sciences for biotech potential.

DYOR; markets fluctuate. Specific query?

[Paul Spencer @BiotechPaul]

@twistednico Smaller part of the business for #PETS but #CVSG will be the bigger loser here.
Vet prices review over fears pet owners are being overcharged
https://t.co/hsdfLnh6iw

[OKYO Pharma LTD @OkyoPharma]

Today OKYO Pharma Announced First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease. A big milestone for the company. #OKYO $OKYO
https://t.co/yIehp9okjt

[Paul Spencer @BiotechPaul]

@KrestTest @HolySmokas Totally agree. @TizianaLS $TLSA has massive potential upside.

[OKYO Pharma LTD @OkyoPharma]

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease. Another big step forward towards our imminent phase 2 trial starting $OKYO #OKYO
https://t.co/lOY79BDR84

[TizianaLifeSciences @TizianaLS]

We are happy to share our new corporate deck on our website today. This includes an exciting update on patient EA2 who has now returned to work part time after being treated with intranasal foralumab.
Full deck: https://t.co/NJpBX1kI3W
$TLSA #MultipleSclerosis #SPMS @MSNewsToday

[TizianaLifeSciences @TizianaLS]

Foralumab In the May edition of @TheLancetInfDis @TheLancet $TLSA
"Gene expression analysis found changes in gene expression patterns (including NKG7, TGF beB1 and GIMAP7) involved with the anti-inflammatory effects of the drug, not only in COVID-19 patients, but also in a patient with multiple sclerosis, meaning the drug may be used for several diseases."
https://t.co/ZXpj2kG5Vr

[TizianaLifeSciences @TizianaLS]

Thank you @proactive_NA for the interview about our news today about #Alzheimers. Link to the interview with the chief medical officer, Matthew Davis can be found below. $TLSA
https://t.co/Kn8Z0eQXv0

[TizianaLifeSciences @TizianaLS]

Today we are happy to announce that we will file an Alzheimer’s IND for Intranasal Foralumab in Q2 2023.
Also an application for a $3m grant will be applied for to support the 2a trial.
$TLSA #Alzheimers #alzheimersdisease #AD
https://t.co/I1clToBpX0

[Paul Spencer @BiotechPaul]

@JohnnyAkzam Think you might want to change your ticker to $TSLA as $TLSA @TizianaLS is a whole different company. 😉

[John Vandermosten @vanjohn10]

@TizianaLS will start Type 1 #diabetes program using intranasal foralumab (IF). The anti-CD3 mAb's ability to regulate inflammation, #FDA approval of TZIELD & easier administration of IF are drivers.
$TLSA PR: https://t.co/FAo0oVMmRM

[BiopharmIQ by Amp @BiopharmIQ]

Biotech News 4/18📰

$BLU 99% Acquired by $GSK $2.0B
$GMDA 43% FDA approval
$MDGL 12% Complete Ph3 enrollment
$IMRX 10% Ph1 initial data;$30M Offering
$MTNB 8% ECCMID'23 presentation
$TLSA 8% New Program initiation
$LSTA 6% Dosed first patient
$HCM 3% NDA accepted
$IMCR 2% New data @AACR'23
$ADAG 2% Ph1b/2 interim data @AACR'23
$PSTV 2% Completed Ph1/Part A
$CLSD 1% Ph2b initiation
$COCP 1% New data @ISIRV conf.
$KRYS 0% Dosed in Ph1

$ARDX -1% NDA resubmitted
$ALKS -1% Separation of Oncology business
$SLS -1% Trial update
$ASMB -1% Ph1a data
$ARQT -2% PDUFA set
$UTHR -2% Upcoming data
$YMAB -3% Preclinical data
$ERAS -3% Ph1b data @AACR'23
$BCRX -6% $450M Financing
$EVAX -11% Ph1/2a data @AACR'23
$ATHX -12% $3.7M Offering
$KNTE -29% Ph1 data
$RLAY -35% Initial data @AACR'23

$XBI $81.2 -0.9%
$IBB $132.4 -0.9%

[Jeff Sun, CFTe @jfsrev]

i like $TLSA much more than $TSLA on its 1 month move. trade the price action without seeking a marriage.

it may just be getting started

[Investing.com News @newsinvesting]

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID - https://t.co/f4mC9hF44e

[Proactive USA @proactive_NA]

$TLSA Tiziana Life Sciences plans to investigate intranasal foralumab for the treatment of Long COVID https://t.co/ZNLB2LoYwn @tizianals #TLSA

[John Vandermosten @vanjohn10]

@TizianaLS to pursue intranasal foralumab for long COVID.
$TLSA Ph2a trial to start after 4Q23 IND & FDA go-ahead.
https://t.co/2a9BdwciSs
Recent @KFF note on long COVID:
https://t.co/DgZIUNquh4

[Open Outcrier @OpenOutcrier]

$TLSA (+4.9% pre) Tiziana Life Sciences (TLSA) to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID - SI

https://t.co/RYcSiOc3dm

[Briefing.com @Briefingcom]

$TLSA: Tiziana Life Sciences announces it plans to investigate intranasal foralumab for the treatment of Long COVID https://t.co/17KNMwY4tS

[Pharma & Life Science News @pharminews]

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
https://t.co/SD85i176Vj
#PharmaNews #LifeScieceNews #BiotechNews #ClinicalResearchNews

[Infectious Disease Tracker @HmpxvT]

⚠️ BREAKING:

Burundi 🇧🇮 quarantines the community of Baziro after an outbreak of a "mysterious disease" resembling hemorrhagic fever appears, killing three.